CXB 909

Drug Profile

CXB 909

Alternative Names: CXB909; KP 544; KRX-0501

Latest Information Update: 27 Jun 2013

Price : $50

At a glance

  • Originator Krenitsky Pharmaceuticals
  • Developer Keryx Biopharmaceuticals
  • Class Antidementias; Nootropics; Pyrimidines; Small molecules
  • Mechanism of Action Choline kinase stimulants; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Neurological disorders

Most Recent Events

  • 27 Jun 2013 Discontinued - Phase-I for Neurological disorders in USA (PO)
  • 27 Jun 2013 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 09 Dec 2011 US FDA approves IND application for CXB 909 in Alzheimer′s disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top